topline

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – December 14,…

2 weeks ago

Foxtale Evolves Into a House of Brands; Introduces Hula Hoop by Foxtale, Following 700-Crore Topline GMV Milestone

The new science-driven bodycare brand strengthens Foxtale's evolution into a category-defining House of Brands and channels existing clinical formulation expertise…

2 weeks ago

Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release

- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…

1 month ago

Baazar Style Retail Crosses 250 Stores, Posts 71% YoY Growth in Q2 FY26

250 Stores: A constant expansion in Value Fashion Segment KOLKATA, India, Oct. 6, 2025 /PRNewswire/ -- Baazar Style Retail Limited (BSRL),…

3 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…

4 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced…

7 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

June 06, 2025 16:05 ET  | Source: PolyPid Ltd. PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD),…

7 months ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

7 months ago